Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Optimizing denosumab treatment strategies to balance skeletal-related events for prevention and osteonecrosis of the jaw risk in metastatic breast cancer patients: A Korean nationwide target trial emulation.

Ji Eun Lee, Seungpil Jung, Hee Kyung Ahn et al. Jun 01, 2026 pp. 1103-1103 10.1200/jco.2026.44.16_suppl.1103

1103 Background: Administration of bone-modifying agents (BMAs) is essential for reducing the incidence of skeletal-relate...

Impact of AI-guided multi-analyte precision oncology–based platform on clinical outcomes in treatment-refractory pan-cancer patients.

Sewanti Atul Limaye, Prashant Agrawal, Aditya V. Shreenivas et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15121

e15121 Background: Refractory solid tumors exhibit profound molecular and functional heterogeneity, frequently requiring r...

Efficacy and safety of second or further line KC1036 in patients with thymoma and thymic carcinoma: A multicenter, single-arm phase II trial.

Wentao Fang, Yongsheng Wang, Zhitao Gu et al. Jun 01, 2026 pp. 8116-8116 10.1200/jco.2026.44.16_suppl.8116

8116 Background: Patients with advanced or recurrent thymoma or thymic carcinoma (T/TC) progressing after platinum-based c...

TroFuse-036/GOG-3123/ENGOT-cx22: A 2-part, phase 3, randomized study of sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) ± bevacizumab (bev) vs standard of care (SoC) as first-line maintenance therapy for PD-L1–positive cervical cancer.

Brian M. Slomovitz, Bradley J. Monk, Krishnansu Sujata Tewari et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps5628

TPS5628 Background: First-line pembro + platinum-doublet chemo ± bev is the preferred SoC for PD-L1-positive stage IVB, pe...

SATURN-STS: Phase II study of neoadjuvant atezolizumab with doxorubicin, concurrent atezolizumab with pre-operative radiation therapy and adjuvant atezolizumab in patients with high-risk surgically resectable extremity and truncal soft tissue sarcoma.

Ahsan Saleem Farooqi, Neeta Somaiah, Christina Lynn Roland et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps11595

TPS11595 Background: High-risk, localized soft tissue sarcoma (STS) remains associated with high rates of distant relapse...

Phase 2 study integrating early palliative care in advanced sarcoma patients for enhanced quality of life (SARQUALITY Trial: NCT06805669): An interim analysis.

Catherine S. Weadick, Natalie Pulenzas, Harleen Toor et al. Jun 01, 2026 pp. 11552-11552 10.1200/jco.2026.44.16_suppl.11552

11552 Background: Patients (pts) with advanced cancer may experience substantial symptom burden that adversely affects qua...

Trends and disparities in mortality due to coexisting respiratory infections and multiple myeloma among middle-aged and older adults in the United States.

Masab Ali, Muhammad Hassan, Humza Saeed et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19541

e19541 Background: Patients with multiple myeloma (MM) are highly susceptible to respiratory infections due to disease- an...

End-of-life anti-cancer treatment (Rx) patterns in patients (pts) with the six most common cancers in the USA.

Umang Swami, Yeonjung Jo, Varun Nandakumar et al. Jun 01, 2026 pp. 12034-12034 10.1200/jco.2026.44.16_suppl.12034

12034 Background: Pts with ≤ 6 months of life expectancy qualify for hospice. However, most pts with advanced/metastatic (...

Dual HER2 blockade with or without taxane induction in HR+/HER2+ metastatic breast cancer: A comparative analysis of clinical outcomes.

Mariah Black, Mostafa Eysha, Rafik ElBeblawy et al. Jun 01, 2026 pp. 1059-1059 10.1200/jco.2026.44.16_suppl.1059

1059 Background: In the era of modern dual HER2 blockade, the necessity of taxane induction for ER+/HER2+ metastatic breas...

Neoadjuvant pyrotinib vs pertuzumab therapy for HER2-positive early breast cancer: The HELEN HER-013 randomized clinical trial.

Jiujun Zhu, Xianfu Sun, Jianghua Qiao et al. Jun 01, 2026 pp. 509-509 10.1200/jco.2026.44.16_suppl.509

509 Background: Docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) is a standard neoadjuvant regimen for stage II–...

Clinical utility analysis of a computational reasoning system on large-scale tumor genomic data.

Dora Lakatos, Robert Doczi, Maria Kocsis-Steinbach et al. Jun 01, 2026 pp. 1625-1625 10.1200/jco.2026.44.16_suppl.1625

1625 Background: Comprehensive tumor molecular testing has become routine in clinical oncology. However, interpretation of...

Risk and protective factors for acral, mucosal, and uveal melanoma in a multi-institutional cohort of veterans and civilians.

Marc S. Hurlbert, Charles Lu, David Perez et al. Jun 01, 2026 pp. 9555-9555 10.1200/jco.2026.44.16_suppl.9555

9555 Background: Melanoma is the 4th most common cancer among US Veterans. Non-acral cutaneous melanoma has well-establish...

Remote, scalable weight-loss interventions after early-stage breast cancer: A systematic review and meta-analysis of randomized controlled trials.

Zaheer Qureshi, Abdur Jamil, Asim Haider et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12748

e12748 Background: Obesity is associated with worse breast cancer outcomes, but whether intentional weight loss improves r...

Gastric cancer incidence, prevalence, and mortality burden in the United States: Retrospective epidemiological trends and burden (1990–2023) with machine learning–based projections to 2050.

Mst. Mahmuda Akter, Ibrahim Khalil, Anika Chowdhury et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16063

e16063 Background: Gastric cancer continues to represent a major global health challenge, though incidence and mortality h...

Automatic pharmacogenomic testing provided on liquid biopsy: Access, prevalence, and integration in a safety net population.

Sujata Ojha, Koushalya Sachdev, William Steele Sessions et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15137

e15137 Background: Pharmacogenomics (PGx) is a rapidly growing tool for precision oncology however remains underutilized i...

Virtual AI-informed immunocyte profiling (VAIP) from H&E as a predictor of multi-cancer prognosis.

Mayukhmala Jana, Arpit Aggarwal, Nikhil Shanbhogue et al. Jun 01, 2026 pp. 3118-3118 10.1200/jco.2026.44.16_suppl.3118

3118 Background: Improved risk stratification is critically needed across multiple cancers to guide treatment decisions. T...

A functional precision medicine strategy to guide patient selection for oncolytic vaccination in <i>NRAS</i> -mutant melanoma.

Luisa Piccin, Sara Mathlouthi, Valentina Salizzato et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e21508

e21508 Background: The NRAS-mutant melanoma subtype represents one of the major challenges in melanoma treatment, as it is...

Association of CT-based deep learning–derived consensus molecular subtypes with survival outcomes in locally advanced colon cancer: A secondary analysis of the phase III OPTICAL trial.

Sifan Qi, Chenchen Xu, Chenchen Li et al. Jun 01, 2026 pp. 3639-3639 10.1200/jco.2026.44.16_suppl.3639

3639 Background: The Consensus Molecular Subtypes (CMS) provide a robust framework for the biological stratification of co...

MAGMA: Multi-arm glioblastoma Australasia phase 3 trial.

Craig Gedye, Katharine Ellen Cuff, Peter Kar Han Lau et al. Jun 01, 2026 pp. 2004-2004 10.1200/jco.2026.44.16_suppl.2004

2004 Background: MAGMA (ACTRN12620000048987; COGNO cooperative trials group) is a prospective, open-label, partial factori...

NRG-GY036: A phase III trial of one vs. two years of maintenance olaparib, with or without bevacizumab, in patients with <i>BRCA1/2</i> -mutated or homologous recombination deficient (HRD+) ovarian cancer following response to first line platinum-based chemotherapy.

Ying L. Liu, Austin Miller, Kathleen N. Moore et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps5634

TPS5634 Background: The profound progression-free survival (PFS) benefit shown in the SOLO-1 and PAOLA-1 randomized clinic...

Clinical outcomes in phase 1 study of EBC-129, a first-in-class, anti–N256-glycosylated CEACAM5 and CEACAM6 antibody-drug conjugate (ADC), in patients with gastroesophageal adenocarcinomas.

Wei-Peng Yong, Matthew C. H. Ng, Sunnie S. Kim et al. Jun 01, 2026 pp. 3033-3033 10.1200/jco.2026.44.16_suppl.3033

3033 Background: Gastro-oesophageal adenocarcinoma (GEA) is an aggressive malignancy with limited treatment options. EBC-1...

Outcomes of malignant peripheral nerve sheath tumors in neurofibromatosis type 1 and sporadic patients: A 25-year experience from a sarcoma referral center.

Clio Coste, Mehdi Brahmi, Franck Tirode et al. Jun 01, 2026 pp. 11570-11570 10.1200/jco.2026.44.16_suppl.11570

11570 Background: Malignant peripheral nerve sheath tumors (MPNST) are rare, aggressive soft-tissue sarcomas frequently as...

3D Structural Revelations of Neoadjuvant Hormonal Therapy Treatment in High Risk Localized Prostate Cancer by Light-Sheet Imaging.

Christopher Hirtsiefer, Htoo Zarni Oo, Joshua Scurll et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17124

e17124 Background: Neoadjuvant hormonal therapy for high-risk (Gleason score ≥ 8), high volume localized prostate cancer p...

Tumor infiltrating lymphocytes (LM103 infusion) in solid tumors: A phase I trial evaluating clinical and immunological anti-tumor activity.

Fenge Li, Chunhua Ma, Yongming Xue et al. Jun 01, 2026 pp. 2537-2537 10.1200/jco.2026.44.16_suppl.2537

2537 Background: Tumor-infiltrating lymphocyte (TIL) therapy has shown clinical promise in melanoma, but its applicability...

Impact of food access and poverty on somatic genomic profiles and clinical outcomes in metastatic breast cancer.

Emily L. Podany, Lorenzo Foffano, Nitin Katakam et al. Jun 01, 2026 pp. 1015-1015 10.1200/jco.2026.44.16_suppl.1015

1015 Background: Patients living in food deserts or experiencing food insecurity have higher cancer mortality rates. While...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page